Naslov
Pentadecapeptide bpc 157 reduces bleeding time and thrombocytopenia after amputation in rats treated with heparin, warfarin, L-Name and L-arginine

Autori
Sikirić, Predrag ; Stupnišek, Mirjana ; Kokot, Antonio ; Drmić, Domagoj ; Hrelec Patrlj, Maša ; Sever, Zdenko ; Radić, Božo ; Bojić, Davor ; Včec, Aleksandar ; Seiwerth, Sven

Izvornik
Cardiologia croatica (1848-543X) 9 (2014), 5-6; 257-257

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
BPC 157, thrombocytopenia, bleeding, NO system, rats

Sažetak
Rationale: BPC 157 is a stable gastric pentadecapeptide recently implicated with a role in hemostasis. While NO is largely implicated in hemostatic mechanisms, in tail-amputation-models under heparin- and warfarin-administration, both the NO-synthase (NOS)-blocker, L-NAME (prothrombotic) and the NOS-substrate L-arginine (antithrombotic) have been little investigated. Objective: To investigate the effects of BPC 157 after LNAME and/or L-arginine administration. Namely, bleeding/-thrombocytopenia (even with anticoagulant administration) after tail- amputation and thrombosis of the abdominal aorta anastomotic site, were both counteracted. BPC 157 also particularly modulates the NO-system and wound-healing, including that of blood vessels. Methods and Results: Tail amputation, and/or i.v.- heparin (10 mg/kg), i.g.-warfarin (1.5 mg/kg/day for 3 days) were used in rats. Medication includes BPC 157, L-NAME, L-arginine, alone and/or together applied accordingly. After (tail) amputation, with or without i.v.-heparin or i.g.-warfarin, BPC 157 (10 µg/kg, 10 ng/kg, i.p., i.v. (heparin), i.g. (warfarin)) always reduced bleeding time and/or haemorrhage and counteracted thrombocytopenia. As for L-NAME and/or L-arginine, we noted: L-arginine (100 mg/kg i.p.)-rats: more bleeding, less/no thrombocytopenia ; L-NAME (5 mg/kg i.p.)-rats: less bleeding (amputation only), but present thrombocytopenia ; L-NAME+L-arginine-rats also exhibited thrombocytopenia: L-NAME counteracted L- arginine-increased bleeding, Larginine did not counteract L-NAME-thrombocytopenia. All of the animals receiving BPC 157 in addition (BPC 157µg+LNAME ; BPC 157µg+L-arginine, BPC 157µg+L- NAME+Larginine), exhibited decreased haemorrhage and markedly counteracted thrombocytopenia. Conclusions: L-NAME (thrombocytopenia), L-arginine (increased haemorrhage) counteraction and BPC 157 (decreased haemorrhage, counteracted thrombocytopenia) with rescue against two different anticoagulants, implicate a BPC 157 modulatory and balancing role with rescued NO- hemostatic mechanisms.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA